Covid-19 Recurrent
Conditions
Keywords
Covid-19, Non Invasive Neuromodulation, Smell
Brief summary
The goal of this clinical trial is to demonstrate the effectiveness of non-invasive Neuromodulation as a therapy in neurological, respiratory and musculoskeletal pathologies derived from the consequences of Covid-19. It will also estimate the impact of non-invasive neuromodulation treatment on the functionality and quality of life of patients with COVID-19 sequelae.The main question it aim to answer is: \- Is non-invasive neuromodulation effective as a therapy in neurological, respiratory and musculoskeletal pathologies derived from the consequences of Covid-19. Researchers will compare non-invasive neuromodulation to a placebo (treatment with the machine turned off). Participants will: * Be evaluated before starting treatment. * Be evaluated 3 weeks after. * Be evaluated at 5 weeks, or 15 sessions or completion of treatment. * Be evaluated 6 weeks after finishing the treatment or 11 weeks after starting treatment.
Detailed description
The waves of Sars-Cov-2 disease continue to be continuous and we are increasingly aware of the consequences it causes both in the respiratory system, musculoskeletal system and in the central and peripheral nervous system. Likewise, non-invasive neuromodulation acts with a pump of ions, generating endogenous stimuli that modulate the central nervous system. The aim of this clinical trial is to demonstrate the effectiveness of non-invasive Neuromodulation as a therapy in neurological, respiratory and musculoskeletal pathologies derived from the consequences of Covid-19. To carry out this study, pain was measured with the visual analogue scale. It was also measured the joint amplitude, a muscle assessment with the help of a strength dynamometer, the patient's independence with the Katz index and the functionality of the lower or upper limbs, depending on the affected joint.
Interventions
DEVICENon invasive neuromodulation therapy
In the 4 studies, the intervention consisted of 15 sessions spread over 5 weeks. Each intervention lasted 60 minutes. The intensity will be programmed in all sessions at Low, following the Arndt-Schulz law. The treatment was distributed in 3 phases: phase 1 of preparation, phase 2 to reduce fatigue and phase 3 to enhance autonomic improvement.
OTHERManual therapy
Common manual therapy administered for said pathology by traditional physiotherapy and therapeutic exercise.
DEVICEPlacebo with non invasive neuromodulation
In the 4 studies, the intervention consisted of 15 sessions spread over 5 weeks. Each intervention lasted 60 minutes. The treatment was carried out with the machine turned off.
Sponsors
Clinica Gema Leon
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Patients between the ages of 18 and 60. * Patients with a positive diagnosis of COVID-19. * Patients with post-COVID-19 sequelae with musculoskeletal, respiratory or neurological symptoms due to taste or smell lasting at least 30 days, with no history of respiratory and/or neurological and/or musculoskeletal diseases. * Patients who signed the informed consent.
Exclusion criteria
* Patients aged before 18 years and after 60 years. * Healthy people with no history of neurological, neurological and/or respiratory and/or musculoskeletal diseases * Patients with secondary diseases that could directly affect the systems to be evaluated who were not diagnosed positive for COVID-19.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ad hoc patient survey | one month | survey of patients about conditions diagnosed during the illness and those they suffer from after infection that are directly related to abnormalities to be assessed. |
| sex, age, vaccination and number of months with symptoms | one month | Nominal variables such as sex, age, vaccination and number of months with symptoms |
| Number of participants with musculoskeletal, respiratory and neurological sequelae of taste and smell after COVID-19 | three months | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| EuroQoL 5-D scale (validated translation into Spanish) for quality of life. | two months | Quality of life related to health. Questionaire with two parts: 1. Descriptive system (5 items). Minimum value: 1 (absence of dificulties). Maximum value: 3 (plenty of difficulties). Optimal value: 1. 2. Visual analogical scale (EVA). Minimum value: 0 (worst imaginable state of health). Maximum value: 100 (best imaginable state of health). Optimal value: 100. |
| upper limb functional index | two months | It is used to evaluate functional impairment in people with upper extremity musculoskeletal dysfunction. 25 questions assessing the level of difficulty in performing activities of daily living using your upper extremities, including household and work activities, hobbies, lifting a bag of food, washing your scalp, pushing on your hands, driving, etc. Patients respond to each item by circling the number that best describes their level of difficulty. |
| lower limb functional index | two months | Valid patient-rated outcome measure to measure lower extremity function. The lower the score the greater the disability. The minimal detectable change is 9 scale points. |
| SDOQ-NS questionnaire for social impairments due to loss of smell | two months | Assess the quality of life impairments of patients with olfactory dysfunction. In a scale of 0 to 3, with higher scores reflecting better olfactory-specific |
| Sensory assessment for pain and light touch | two months | The sensory exam involves evaluation of pain and light touch. Test pain using a sharp object. At minimum, test the shoulders, arms and legs, comparing side to side and proximal to distal areas. In any area where the patient complains of sensory loss or hypersensitivity, more detailed testing may be required. For light touch, uses your fingertips or a wisp of cotton, lightly stroke the skin and determine if the patient feels this symmetrically in all areas tested. At minimum, test the shoulders, arms and legs, comparing side to side and proximal to distal areas. |
| Sadoul's dyspnea rating scale. | two months | Respiratory evaluation. Minimum value: 0 (absence of dyspnea). Maximum value: 5 (dyspnea occurs with minimal efforts). Optimal value: 0. |
| measurement of lung function with spirometry and lung volume testing | three months | measurement of lung function with spirometry and lung volume testing (measurement of maximum inspiratory and expiratory pressures (Pimax and Pemax, respectively) |
| Visual analogue scale (VAS), for pain assessment | two months | Intensity of pain. Minimum value: 0 (absence of pain). Maximum value: 10 (unbearable pain). Optimal value: 0. |
| SF12 Quality of Life Questionnaire | two months | Assesses the impact of health on an individual's everyday life. Scores above 50 indicate a better-than-average health-related quality of life, while scores below 50 suggest below-average health. |
| Brief Smell Identification Test: Assessment of smell. | two months | Assesses the ability to recognize familiar odors. A 12-item questionnaire. For each item, a microcapsule containing a familiar odor is scratched with a pencil and placed under the participant's nose. The total score is the number of odors that are correctly recognized. Missing responses are assigned a partial score of 0.25. If more than 2 responses are missing, the entire test is treated as missing. |
Countries
Spain
Contacts
Primary ContactGEMA LEÓN BRAVO
Backup ContactGEMA LEÓN BRAVO
Outcome results
None listed